Disease · MONDO_0005105
Comparisons in its trials322
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 322
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab/Vibostolimab vs Pembrolizumab: deaths from any cause | 6 of 701 | 1 of 701 | 1,402 | NCT05665595 | Trial comparisons |
| Pembrolizumab/Vibostolimab vs Pembrolizumab: serious adverse events | 109 of 698 | 57 of 700 | 1,398 | NCT05665595 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause | 130 of 654 | 131 of 647 | 1,301 | NCT02506153 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): serious adverse events | 23 of 565 | 125 of 639 | 1,204 | NCT02506153 | Trial comparisons |
| Treatment 1 vs Treatment 2: deaths from any cause | 86 of 547 | 76 of 546 | 1,093 | NCT05002569 | Trial comparisons |
| Dabrafenib+Trametinib (On-treatment) vs Dabrafenib+Trametinib (Post-treatment Follow-up): deaths from any cause | 1 of 552 | 47 of 537 | 1,089 | NCT03551626 | Trial comparisons |
| Treatment 1 vs Treatment 2: serious adverse events | 174 of 543 | 121 of 545 | 1,088 | NCT05002569 | Trial comparisons |
| Pembrolizumab vs Placebo: deaths from any cause | 25 of 514 | 35 of 505 | 1,019 | NCT02362594 | Trial comparisons |
| Pembrolizumab vs Placebo: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 70 of 509 | 18 of 502 | 1,011 | NCT02362594 | Trial comparisons |
| Pembrolizumab vs Placebo: Number of Participants Who Experienced At Least 1 Adverse Event (AE) | 475 of 509 | 453 of 502 | 1,011 | NCT02362594 | Trial comparisons |
| Pembrolizumab vs Placebo: serious adverse events | 128 of 509 | 82 of 502 | 1,011 | NCT02362594 | Trial comparisons |
| Observation vs Interferon Alfa-2b: serious adverse events | 20 of 439 | 325 of 568 | 1,007 | NCT00003641 | Trial comparisons |
| Dabrafenib + Trametinib Combination Therapy vs Dabrafenib and Trametinib Placebos: deaths from any cause | 4 of 435 | 1 of 432 | 867 | NCT01682083 | Trial comparisons |
| Dabrafenib + Trametinib Combination Therapy vs Dabrafenib and Trametinib Placebos: serious adverse events | 155 of 435 | 44 of 432 | 867 | NCT01682083 | Trial comparisons |
| Temozolomide vs Dacarbazine: serious adverse events | 124 of 419 | 100 of 421 | 840 | NCT00091572 | Trial comparisons |
| Arm I (Carboplatin + Paclitaxel + Sorafenib) vs Arm II (Carboplatin + Paclitaxel+Placebo): serious adverse events | 332 of 393 | 311 of 397 | 790 | NCT00110019 | Trial comparisons |
| Bempegaldesleukin + Nivolumab vs Nivolumab: deaths from any cause | 170 of 391 | 173 of 392 | 783 | NCT03635983 | Trial comparisons |
| Bempegaldesleukin + Nivolumab vs Nivolumab: serious adverse events | 161 of 388 | 172 of 382 | 770 | NCT03635983 | Trial comparisons |
| 10 MG/KG IPILIMUMAB vs 3 MG/KG IPILIMUMAB: serious adverse events | 245 of 364 | 194 of 362 | 726 | NCT01515189 | Trial comparisons |
| Arm A: Relatlimab + Nivolumab vs Arm B: Nivolumab: The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation | 69 of 355 | 41 of 359 | 714 | NCT03470922 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005105/comparisons